Researcher.Life Logo

Acta Pharmaceutica : Impact Factor & More

eISSN: 1846-9558pISSN: 1330-0075
JournalOpen Access

Key Metrics

CiteScore
4.5
Impact Factor
< 5
SJR
Q3Pharmacology
SNIP
0.9
Recommended pre-submission checks
Powered by Paperpal by Editage

Acta Pharmaceutica Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SCIENDO
Language English
Frequency Quarterly
Article Processing ChargesEUR 900
Publication Time20
Editorial Review ProcessDouble anonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorCroatian Pharmaceutical Society
FrequencyQuarterly
Publication Start Year1951
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 20
Editorial Review Detail
Editorial TeamVisit website
Review ProcessDouble anonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Acta Pharmaceutica ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Acta Pharmaceutica

Pelargonidin protects retinal ganglion cells in a streptozotocin-induced diabetic rat model by reducing intraocular pressure, suppressing TGF-β and activating JAK2/STAT3 signalling pathway.
  • 9 Apr 2026
  • Acta pharmaceutica (Zagreb, Croatia)
H3 relaxin mediated neuroprotection in Alzheimer's disease pathology induced by streptozotocin in mouse models: Impact on memory improvement, autophagy and PI3K/Akt-mTOR signalling pathway.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Sexually dimorphic and time-dependent influence of active avoidance learning by vilazodone in C57BL/6J mice.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Predictive analytical workflow for rapid structure elucidation and in silico toxicological qualification of an unidentified impurity in cefixime granules for oral suspension.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Beneficial effect of omega-3 fatty acids supplementation on leaky gut, inflammation and oxidative stress in propionic acid-induced autism in aged rats.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
The effect of astragaloside IV on a model of isoproterenol-induced hypertrophic injury in H9c2 cells.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Pelargonidin protects retinal ganglion cells in a streptozotocin-induced diabetic rat model by reducing intraocular pressure, suppressing TGF-β and activating JAK2/STAT3 signalling pathway.
  • 9 Apr 2026
  • Acta pharmaceutica (Zagreb, Croatia)
H3 relaxin mediated neuroprotection in Alzheimer's disease pathology induced by streptozotocin in mouse models: Impact on memory improvement, autophagy and PI3K/Akt-mTOR signalling pathway.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Sexually dimorphic and time-dependent influence of active avoidance learning by vilazodone in C57BL/6J mice.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Predictive analytical workflow for rapid structure elucidation and in silico toxicological qualification of an unidentified impurity in cefixime granules for oral suspension.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
Beneficial effect of omega-3 fatty acids supplementation on leaky gut, inflammation and oxidative stress in propionic acid-induced autism in aged rats.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)
The effect of astragaloside IV on a model of isoproterenol-induced hypertrophic injury in H9c2 cells.
  • 1 Mar 2026
  • Acta pharmaceutica (Zagreb, Croatia)

FAQs on Acta Pharmaceutica